• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Novavax Inc.

    7/10/24 6:16:55 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NVAX alert in real time by email
    SC 13G/A 1 Novavax_Inc.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING NOVAVAX INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 670002401 (CUSIP NUMBER) 06/30/2024 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COVER PAGE SHALL BE FILLED OUT FOR A REPORTING PERSON`S INITIAL FILING ON THIS FORM WITH RESPECT TO THE SUBJECT CLASS OF SECURITIES, AND FOR ANY SUBSEQUENT AMENDMENT CONTAINING INFORMATION WHICH WOULD ALTER THE DISCLOSURES PROVIDED IN A PRIOR COVER PAGE. THE INFORMATION REQUIRED IN THE REMAINDER OF THIS COVER PAGE SHALL NOT BE DEEMED TO BE "FILED" FOR THE PURPOSE OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934 ("ACT") OR OTHERWISE SUBJECT TO THE LIABILITIES OF THAT SECTION OF THE ACT BUT SHALL BE SUBJECT TO ALL OTHER PROVISIONS OF THE ACT (HOWEVER, SEE THE NOTES). CUSIP NO:670002401 13G Page 2 of 5 Pages 1. NAME OF REPORTING PERSON: STATE STREET CORPORATION I.R.S. IDENTIFICATION NO. OF THE ABOVE PERSON: 04-2456637 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP NOT APPLICABLE 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION BOSTON, MASSACHUSETTS 5. SOLE VOTING POWER 0 SHARES 6. SHARED VOTING POWER 5,597,236 7. SOLE DISPOSITIVE POWER 0 SHARES 8. SHARED DISPOSITIVE POWER 6,066,179 9. AGGREGATED AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,066,179 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES NOT APPLICABLE 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 4.32% 12. TYPE OF REPORTING PERSON HC CUSIP NO: 670002401 13G Page 3 of 5 Pages ITEM 1. (A) NAME OF ISSUER NOVAVAX INC (B) ADDRESS OF ISSUER`S PRINCIPAL EXECUTIVE OFFICES 20 FIRSTFIELD ROAD GAITHERSBURG MD 20878 UNITED STATES ITEM 2. (A) NAME OF PERSON FILING STATE STREET CORPORATION (B) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE STATE STREET FINANCIAL CENTER 1 CONGRESS STREET, SUITE 1 BOSTON, MA 02114-2016 (FOR ALL REPORTING PERSONS) (C) CITIZENSHIP: SEE ITEM 4 (CITIZENSHIP OR PLACE OF ORGANIZATION) OF COVER PAGES (D) TITLE OF CLASS OF SECURITIES COMMON STOCK (E) CUSIP NUMBER: 670002401 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A: SEE ITEM 12(TYPE OF REPORTING PERSON) OF THE COVER PAGE FOR EACH REPORTING PERSON AND THE TABLE BELOW, WHICH EXPLAINS THE MEANING OF THE TWO LETTER SYMBOLS APPEARING IN ITEM 12 OF THE COVER PAGES. SYMBOL CATEGORY BK BANK AS DEFINED IN SECTION 3(A) (6) OF THE ACT. IC INSURANCE COMPANY AS DEFINED IN SECTION 3 (A) (19) OF THE ACT IC INVESTMENT COMPANY REGISTERED UNDER SECTION 8 OF THE INVESTMENT COMPANY ACT OF 1940. IA AN INVESTMENT ADVISOR IN ACCORDANCE WITH RULE 13D-1(B) (1) (II) (E). EP AN EMPLOYEE BENEFIT PLAN OR ENDOWMENT FUND IN ACCORDANCE WITH RULE 13D-1(B) (1) (II) (F) . HC A PARENT HOLDING COMPANY OR CONTROL PERSON IN ACCORDANCE WITH RULE 13D-1(B)(1)(II) (G). SA A SAVINGS ASSOCIATIONS AS DEFINED IN SECTION 3(B) OF THE FEDERAL DEPOSIT INSURANCE ACT (12 U.S.C. 1813). CP A CHURCH PLAN THAT IS EXCLUDED FROM THE DEFINITION OF AN INVESTMENT COMPANY UNDER SECTION 3(C)(14) OF THE INVESTMENT COMPANY ACT OF 1940. CUSIP NO:670002401 13G Page 4 of 5 Pages ITEM 4. OWNERSHIP THE INFORMATION SET FORTH IN ROWS 5 THROUGH 11 OF THE COVER PAGE HERETO FOR EACH OF THE REPORTING PERSONS IS INCORPORATED HEREIN BY REFERENCE. ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF CLASS YES ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON NOT APPLICABLE ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON SEE EXHIBIT 1 ATTACHED HERETO ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP NOT APPLICABLE ITEM 9. NOTICE OF DISSOLUTION OF GROUP NOT APPLICABLE CUSIP NO:670002401 13G Page 5 of 5 Pages ITEM 10. CERTIFICATION BY SIGNING BELOW I CERTIFY THAT, TO THE BEST OF MY KNOWLEDGE AND BELIEF, THE SECURITIES REFERRED TO ABOVE WERE ACQUIRED AND ARE HELD IN THE ORDINARY COURSE OF BUSINESS AND WERE NOT ACQUIRED AND ARE NOT HELD FOR THE PURPOSE OR WITH THE EFFECT OF CHANGING OR INFLUENCING THE CONTROL OF THE ISSUER OF THE SECURITIES AND WERE NOT ACQUIRED AND ARE NOT HELD IN CONNECTION WITH OR AS A PARTICIPANT IN ANY TRANSACTION HAVING THAT PURPOSE OR EFFECT. SIGNATURES AFTER REASONABLE INQUIRY AND TO THE BEST OF HIS KNOWLEDGE AND BELIEF, EACH OF THE UNDERSIGNED CERTIFIES THAT THE INFORMATION SET FORTH IN THIS STATEMENT IS TRUE, COMPLETE AND CORRECT. STATE STREET CORPORATION ELIZABETH SCHAEFER SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER EXHIBIT 1 THE FOLLOWING TABLE LISTS THE IDENTITY AND ITEM 3 CLASSIFICATION OF EACH SUBSIDIARY OF STATE STREET CORPORATION, THE PARENT HOLDING COMPANY, THAT BENEFICIALLY OWNS THE ISSUER`S SECURITIES. PLEASE REFER TO ITEM 3 OF THE ATTACHED SCHEDULE 13G FOR A DESCRIPTION OF EACH OF THE TWO-LETTER SYMBOLS REPRESENTING THE ITEM 3 CLASSIFICATION BELOW. SUBSIDIARY ITEM 3 CLASSIFICATION SSGA FUNDS MANAGEMENT, INC. IA STATE STREET GLOBAL ADVISORS EUROPE LIMITED IA STATE STREET GLOBAL ADVISORS LIMITED IA STATE STREET GLOBAL ADVISORS TRUST COMPANY IA STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED IA NOTE: ALL OF THE LEGAL ENTITIES ABOVE ARE DIRECT OR INDIRECT SUBSIDIARIES OF STATE STREET CORPORATION.
    Get the next $NVAX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVAX

    DatePrice TargetRatingAnalyst
    2/28/2025$19.00Buy
    BTIG Research
    7/30/2024$8.00Neutral → Underweight
    JP Morgan
    5/10/2024$4.00 → $12.00Underperform → Neutral
    BofA Securities
    5/10/2024Underweight → Neutral
    JP Morgan
    8/9/2023$15.00Neutral → Buy
    B. Riley Securities
    4/20/2023$55.00 → $10.00Outperform → Market Perform
    TD Cowen
    3/1/2023$29.00 → $10.00Buy → Neutral
    B. Riley Securities
    1/9/2023$74.00 → $37.00Buy
    B. Riley Securities
    More analyst ratings

    $NVAX
    Financials

    Live finance-specific insights

    See more
    • Novavax Reports First Quarter 2025 Financial Results and Operational Highlights

      FDA feedback on COVID-19 BLA suggests pathway to approval upon alignment on study parameters for the postmarketing commitment requested by FDASHIELD-Utah study demonstrates that Nuvaxovid® resulted in fewer and less severe reactogenicity symptoms when compared to marketed mRNA vaccine; Nuvaxovid recipients experienced approximately 39% fewer symptoms on averageData presented at World Vaccine Congress showcases Matrix-M® utility when co-administered with a broad array of vaccine platforms and diseasesStrengthened partnership with Takeda in Japan, the third largest pharmaceutical market, with significant improvement in financial termsRaises full year 2025 revenue framework to between $975 mill

      5/8/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax to Report First Quarter 2025 Financial Results on May 8, 2025

      GAITHERSBURG, Md., May 1, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its first quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, May 8, 2025. Details of the event and replay are as follows: Conference call details: Date: May 8, 2025 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/43UHjFq Dial-in number: (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International) Webcast: ir.novavax.com/events Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants

      5/1/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

      Transitioned lead commercial responsibility of Nuvaxovid™ COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in the fourth quarter of 2024 and $682 million for the full year 2024 Achieved $50 million milestone under Sanofi agreement associated with the pediatric clinical trial database lock for the first cohortCompleted $200 million sale of Czech Republic manufacturing facility to Novo Nordisk; reduces annual costs by approximately $80 millionAdvanced pipeline programs, based on proven and innovative technology platformEnded full year 2024 with over $1 billion in Cash and accounts receivablesProvides 2025 financial guidance and revenue framew

      2/27/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NVAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

      For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

      9/3/24 2:26:49 PM ET
      $NVAX
      $PFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

      For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

      8/30/24 2:26:48 PM ET
      $NVAX
      $PFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • October 3, 2023 - FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants

      For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO

      10/3/23 2:56:27 PM ET
      $NVAX
      $PFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $NVAX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Novavax Reports First Quarter 2025 Financial Results and Operational Highlights

      FDA feedback on COVID-19 BLA suggests pathway to approval upon alignment on study parameters for the postmarketing commitment requested by FDASHIELD-Utah study demonstrates that Nuvaxovid® resulted in fewer and less severe reactogenicity symptoms when compared to marketed mRNA vaccine; Nuvaxovid recipients experienced approximately 39% fewer symptoms on averageData presented at World Vaccine Congress showcases Matrix-M® utility when co-administered with a broad array of vaccine platforms and diseasesStrengthened partnership with Takeda in Japan, the third largest pharmaceutical market, with significant improvement in financial termsRaises full year 2025 revenue framework to between $975 mill

      5/8/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax to Participate in BofA Securities 2025 Health Care Conference

      GAITHERSBURG, Md., May 7, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced that it will participate in the BofA Securities 2025 Health Care Conference. Conference Details: Fireside Chat Date: Wednesday, May 14, 2025 Time: 3:00 – 3:30 p.m. Pacific Time (PT) Location: Las Vegas, NV Conference Event: Investor Meetings Date: Wednesday, May 14, 2025 A webcast of the fireside chat will be available on the Events & Presentations page of the Company's website at ir.novavax.com. A replay of the webcast will be available for 30 days. About NovavaxNovavax, Inc. (NASDAQ:NVAX) tackles some of the world's most significant health challenges by leveraging its scientific expertise in vaccines

      5/7/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan

      Improved financial terms for Novavax and streamlined operations will help both companies better meet the needs of the Japanese market Nuvaxovid®, a protein-based, non-mRNA COVID-19 vaccine, will continue to be available in Japan, the world's third largest pharmaceutical marketGAITHERSBURG, Md., May 5, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) has updated the terms of the previously announced collaboration and licensing agreement (CLA) with Takeda. The improved financial terms of the amended agreement for the development, manufacturing and commercialization of Nuvaxovid® in Japan include an upfront payment, payment related to the 2024/2025 season, annual milestones associated with regu

      5/5/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NVAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Novavax Inc.

      SC 13G/A - NOVAVAX INC (0001000694) (Subject)

      11/12/24 4:46:17 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Novavax Inc.

      SC 13G/A - NOVAVAX INC (0001000694) (Subject)

      11/4/24 1:19:04 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Novavax Inc.

      SC 13G/A - NOVAVAX INC (0001000694) (Subject)

      7/10/24 6:16:55 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NVAX
    Leadership Updates

    Live Leadership Updates

    See more

    $NVAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Novavax Appoints Charles Newton to Board of Directors

      GAITHERSBURG, Md., April 29, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr. Newton brings extensive experience in public markets and healthcare investment banking to his role on the Novavax Board of Directors. "Charles brings a wealth of expertise across corporate finance and capital markets to Novavax," said John C. Jacobs, President and Chief Executive Officer, Novavax. "The knowledge he brings to our already experienced board will be invaluable as we continue to execute our corp

      4/29/25 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brian Rosen, Commercial Strategy Senior Executive, Appointed as Director of Capstone Companies, Inc.

      Capstone Companies, Inc. (OTCQB:CAPC) announced today the appointment of Brian Rosen as a non-employee director, effective January 20, 2025. Mr. Rosen has extensive experience in marketing, business development, contract negotiation and government relations as well as experience as a member of two public companies' management. He served as Senior Vice President, Global Market Access, Public Policy & Alliances (2021 - 2023), Senior Vice President, Commercial Strategy (2018 - 2021) and Vice President, Market Access, Policy, & Government Affairs (2015 - 2017) with Novavax, Inc. (NASDAQ:NVAX). Before Novavax, Inc., Mr. Rosen served as Chief Policy, Advocacy & Patient Services Officer (2014 -

      1/23/25 9:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development

      Ruxandra Draghia-Akli, MD, PhD brings more than 20 years of extensive clinical, corporate and global public health expertise to support Novavax's transition to an R&D-focused organizationDr. Draghia-Akli will be integral in strategically evaluating the Company's pipeline and opportunities for its Matrix-M™ adjuvant and protein-based technology platformGAITHERSBURG, Md., Sept. 25, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Ruxandra Draghia-Akli, MD, PhD, will join the Company in November 2024 as Executive Vice President and Head of Research & Development (R&D). Dr. Draghia-Akli brings m

      9/25/24 8:00:00 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Newton Charles W.

      4 - NOVAVAX INC (0001000694) (Issuer)

      4/29/25 8:08:08 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Newton Charles W.

      3 - NOVAVAX INC (0001000694) (Issuer)

      4/29/25 8:06:39 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Shiver John W.

      4 - NOVAVAX INC (0001000694) (Issuer)

      3/12/25 8:04:38 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NVAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Novavax with a new price target

      BTIG Research initiated coverage of Novavax with a rating of Buy and set a new price target of $19.00

      2/28/25 7:28:04 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax downgraded by JP Morgan with a new price target

      JP Morgan downgraded Novavax from Neutral to Underweight and set a new price target of $8.00

      7/30/24 6:25:22 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax upgraded by BofA Securities with a new price target

      BofA Securities upgraded Novavax from Underperform to Neutral and set a new price target of $12.00 from $4.00 previously

      5/10/24 1:12:36 PM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NVAX
    SEC Filings

    See more
    • Novavax Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NOVAVAX INC (0001000694) (Filer)

      5/8/25 8:26:56 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Novavax Inc.

      10-Q - NOVAVAX INC (0001000694) (Filer)

      5/8/25 7:59:11 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Novavax Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - NOVAVAX INC (0001000694) (Filer)

      5/5/25 9:25:23 AM ET
      $NVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care